GO:0038106 choriogonadotropin hormone binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038106 choriogonadotropin hormone binding describes the molecular function of binding to choriogonadotropin (hCG), a heterodimeric glycoprotein hormone with an alpha subunit shared with LH, FSH and TSH and a unique beta subunit.
• The principal receptor mediating this binding is LHCGR (luteinizing hormone/choriogonadotropin receptor), a G-protein-coupled receptor with a large extracellular domain containing leucine-rich repeats.
• High-affinity hCG binding involves multiple extracellular domain residues and is modulated by exoloop 2 of the receptor, distinguishing it from LH binding.
• Receptor activation is a distinct step from hormone binding; Asp397 in the receptor is critical for activation but not for binding.
• Small-molecule modulators can selectively target LHCGR versus TSHR, offering pharmacological tools to probe binding and signaling.
• Studying GO:0038106 is relevant to reproductive biology, gestational disorders, and cancers expressing hCG or LHCGR, and benefits from CRISPR-based models of receptor and ligand genes.
Description
Choriogonadotropin hormone binding (GO:0038106) is a molecular function defined as binding to choriogonadotropin hormone, a heterodimer whose alpha subunit is identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), and whose beta subunit is unique. This function is central to the action of human chorionic gonadotropin (hCG), a hormone produced during pregnancy and by certain tumors, which exerts its effects by binding to specific receptors on target cells. The primary receptor for hCG is the luteinizing hormone/choriogonadotropin receptor (LHCGR), a member of the glycoprotein hormone receptor family. Understanding the molecular details of this binding event is essential for reproductive endocrinology, drug discovery, and cancer biology. The binding of hCG to LHCGR is a high-affinity interaction that involves multiple regions of the receptor extracellular domain, including leucine-rich repeats 1-6 and exoloop 2. Structural studies of full-length glycoprotein hormone receptor signalling complexes have provided near-atomic resolution views of how hCG engages LHCGR and triggers downstream signaling. Mutational analyses have shown that different extracellular domain residues dictate binding affinities for LH versus hCG, indicating that the binding interface is not uniform across ligands. Furthermore, receptor activation is a step distinct from hormone binding, as illustrated by mutations such as Asp397 that impair activation without abolishing binding. For researchers, GO:0038106 represents a tractable molecular function to interrogate using gene editing, biochemical assays, and structural biology. Small-molecule modulators that selectively bind LHCGR or TSHR have been developed, demonstrating that the binding pocket can be targeted pharmacologically. Deletions within the extracellular loops of LHCGR can reduce binding affinity for ovine LH but not human hCG, highlighting ligand-specific determinants. This article reviews the mechanism, key genes, disease relevance, and experimental approaches for studying choriogonadotropin hormone binding, with a focus on CRISPR-based models and functional genomics.
choriogonadotropin hormone binding At A Glance
| GO ID | GO:0038106 |
|---|---|
| GO term | choriogonadotropin hormone binding |
| Ontology | molecular_function |
| Synonym | chorionic gonadotrophin binding; chorionic gonadotropin binding |
| Definition | Binding to choriogonadotropin hormone, a heterodimer, with an alpha subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), and a unique beta subunit. |
| Major function | High-affinity recognition of hCG by receptors such as LHCGR, enabling hormone-specific signaling. |
| Primary receptor | LHCGR (luteinizing hormone/choriogonadotropin receptor) |
| Key structural features | Leucine-rich repeats 1-6 and exoloop 2 of the receptor extracellular domain |
| Related ligands | hCG (choriogonadotropin), LH, FSH, TSH share the alpha subunit |
| Disease relevance | Reproductive disorders, gestational diseases, and hCG/LHCGR-expressing cancers |
What Is GO:0038106?
In simple terms, GO:0038106 describes the ability of a protein or molecular complex to physically bind to choriogonadotropin hormone (hCG). Choriogonadotropin is a heterodimeric glycoprotein hormone composed of an alpha subunit that is shared with LH, FSH, and TSH, and a beta subunit that is unique to hCG. This binding function is typically mediated by the extracellular domain of the luteinizing hormone/choriogonadotropin receptor (LHCGR), which recognizes hCG with high affinity and specificity. The term encompasses the initial recognition and stable association between hCG and its binding partners, which is a prerequisite for receptor activation and downstream signaling.
Why Is choriogonadotropin hormone binding Important in Cell Biology?
Choriogonadotropin hormone binding is a critical molecular function because it initiates the biological actions of human chorionic gonadotropin, a hormone essential for pregnancy maintenance and also implicated in tumorigenesis. The specificity of this binding event ensures that hCG can selectively activate LHCGR without cross-reacting with other glycoprotein hormone receptors, despite sharing the alpha subunit with LH, FSH, and TSH. Structural and mutational studies have revealed that high-affinity binding depends on multiple extracellular domain elements, and that binding can be uncoupled from receptor activation. Understanding this function at the molecular level informs the design of contraceptives, fertility treatments, and targeted therapies for cancers that exploit hCG signaling.
• Essential for pregnancy: hCG binding to LHCGR supports corpus luteum maintenance and progesterone production.
• Reproductive disorders: mutations or polymorphisms in LHCGR can alter hCG binding and cause conditions such as Leydig cell hypoplasia or precocious puberty.
• Cancer biology: hCG is expressed by some tumors, and its binding to LHCGR may promote proliferation; targeting this interaction is a therapeutic strategy.
• Drug discovery: small-molecule modulators that selectively bind LHCGR versus TSHR provide leads for fertility regulation and cancer treatment.
• Structural insights: cryo-EM structures of full-length receptor-hormone complexes reveal the binding interface and activation mechanism.
• Ligand discrimination: different extracellular domain residues dictate binding affinity for LH versus hCG, explaining hormone specificity.
• Receptor activation: Asp397 is important for activation but not binding, highlighting separable functional steps.
• Experimental models: CRISPR knockout of LHCGR or hCG subunits enables functional dissection of binding in cell models.
• Biochemical assays: binding affinity can be measured using radioligand or surface plasmon resonance, guiding structure-activity studies.
• Translational relevance: understanding hCG binding may improve diagnosis and monitoring of gestational trophoblastic diseases.
Molecular Mechanism of choriogonadotropin hormone binding
Hormone recognition by the receptor extracellular domain
In simple terms: The receptor uses a large outer domain to grab the hormone.
The luteinizing hormone/choriogonadotropin receptor (LHCGR) possesses a large extracellular domain containing leucine-rich repeats that are involved in hormone binding. Mutational analyses of the full-length receptor suggest that leucine-rich repeats 1-6 contribute to the binding interface. High-affinity binding of human choriogonadotropin to the receptor exodomain is influenced by exoloop 2, indicating that regions outside the primary ligand-binding pocket modulate affinity. Deletions of portions of the extracellular loops decrease binding affinity for ovine luteinizing hormone but not human choriogonadotropin, revealing ligand-specific structural requirements.
Ligand-specific determinants of binding affinity
In simple terms: Different parts of the receptor decide how tightly LH versus hCG binds.
The differential binding affinities of LHCGR for LH and hCG are dictated by different extracellular domain residues. This means that the binding interface is not identical for the two hormones, allowing the receptor to discriminate between them despite their shared alpha subunit. Such discrimination is important because hCG and LH have distinct physiological roles and temporal expression patterns.
Binding versus activation: Asp397 and receptor activation
In simple terms: Binding the hormone and turning the receptor on are two separate steps.
Receptor activation is distinct from hormone binding in intact lutropin-choriogonadotropin receptors, and Asp397 is important for receptor activation but not for hormone binding. This separation implies that high-affinity binding is necessary but not sufficient for signaling, and that conformational changes after binding are required to activate the receptor. Structural studies of full-length glycoprotein hormone receptor signalling complexes have provided insights into how hormone binding leads to receptor activation.
Pharmacological modulation of binding
In simple terms: Small molecules can interfere with or mimic hormone binding.
Small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors have been evaluated, revealing structure-activity relationships and selective binding patterns. These compounds can bind to the receptor and modulate its activity, demonstrating that the hormone-binding pocket is druggable. Such modulators are useful tools to probe the binding mechanism and may lead to therapeutics for reproductive and thyroid disorders.
Structural basis of hormone-receptor complexes
In simple terms: 3D structures show exactly how the hormone fits into the receptor.
Structures of full-length glycoprotein hormone receptor signalling complexes have been determined, providing a detailed view of how hCG binds to LHCGR and how the receptor changes conformation upon activation. These structures confirm the involvement of the extracellular domain and reveal the overall architecture of the complex. They also help explain how the shared alpha subunit and unique beta subunit of hCG contribute to binding specificity.
Key Genes Involved in GO:0038106 choriogonadotropin hormone binding
The following genes encode the hormone subunits and receptor proteins that directly participate in or regulate choriogonadotropin hormone binding (GO:0038106).
| Gene | Major Role | Research Relevance |
|---|---|---|
| LHCGR | Receptor for LH and hCG; mediates high-affinity binding and signaling | Primary binding partner; mutations affect binding affinity and activation |
| CGA | Alpha subunit shared by hCG, LH, FSH, and TSH | Forms the heterodimer required for receptor binding |
| CGB | Beta subunit unique to hCG | Confers specificity for LHCGR binding |
| CGB3 | Beta subunit variant of hCG | May influence hCG levels and binding |
| CGB5 | Beta subunit variant of hCG | Associated with pregnancy and tumor marker expression |
| CGB7 | Beta subunit variant of hCG | Expressed in placenta and some tumors |
| CGB8 | Beta subunit variant of hCG | Contributes to hCG heterogeneity |
| LHB | Beta subunit of luteinizing hormone | Shares receptor with hCG but binds with different affinity |
| FSHB | Beta subunit of follicle-stimulating hormone | Related glycoprotein hormone; not a ligand for LHCGR |
| TSHB | Beta subunit of thyroid-stimulating hormone | Related glycoprotein hormone; binds TSHR |
| TSHR | Receptor for TSH; structurally related to LHCGR | Target of small-molecule modulators; comparison to LHCGR |
| GNAS | G protein alpha subunit mediating cAMP signaling downstream of LHCGR | Effector of receptor activation after hormone binding |
| ARRB1 | Beta-arrestin 1 involved in receptor desensitization | Regulates LHCGR signaling after binding |
| ARRB2 | Beta-arrestin 2 involved in receptor internalization | Modulates post-binding events |
| PRKACA | Protein kinase A catalytic subunit | Mediates downstream signaling following receptor activation |
| PRKACB | Protein kinase A catalytic subunit beta | Alternative PKA subunit in signaling |
| CREB1 | Transcription factor activated by cAMP | Drives gene expression changes after hCG binding |
How Is choriogonadotropin hormone binding Regulated?
The binding of choriogonadotropin to its receptor is regulated at multiple levels. Receptor availability at the cell surface is controlled by trafficking and maturation, as deletions in extracellular loops can prevent formation of mature cell surface receptor and thereby reduce binding affinity for ovine LH. Exoloop 2 of the receptor modulates high-affinity hormone binding, suggesting that conformational dynamics influence the binding event. Hormone levels themselves are regulated by expression of the alpha and beta subunit genes, with the unique beta subunit of hCG determining specificity. Additionally, small-molecule modulators can act as positive or negative allosteric regulators of binding and activation. Post-binding, receptor activation is distinct from binding and involves specific residues such as Asp397.
choriogonadotropin hormone binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LHCGR | Leydig cell hypoplasia, precocious puberty, infertility | Knockout or point-mutation in cell lines; cAMP assays |
| CGB | Gestational trophoblastic disease, tumor marker | Overexpression or knockout in trophoblast models |
| CGA | Pituitary dysfunction, infertility | Knockout in gonadotrope cell lines |
| TSHR | Graves' disease, thyroid nodules | Selective small-molecule binding assays |
| GNAS | McCune-Albright syndrome, endocrine tumors | Knock-in of activating mutations |
Reproductive disorders and LHCGR mutations
Alterations in LHCGR that affect hormone binding can lead to reproductive disorders. Mutations that impair binding or activation may cause Leydig cell hypoplasia, while activating mutations can cause precocious puberty. The differential binding affinities for LH and hCG are dictated by different extracellular domain residues, so mutations in these regions can selectively affect one hormone over the other. Understanding these molecular defects helps in genetic diagnosis and counseling.
hCG-expressing cancers and LHCGR signaling
Human chorionic gonadotropin is ectopically expressed in some tumors, and its binding to LHCGR may promote tumor growth. Small-molecule modulators that selectively target LHCGR could be developed as anticancer agents. The structural basis of hormone binding, as revealed by cryo-EM, provides a template for designing inhibitors. Therefore, GO:0038106 is directly relevant to cancer biology and targeted therapy.
Gestational trophoblastic disease and pregnancy-related conditions
hCG is a key hormone in pregnancy, and abnormal hCG levels are associated with gestational trophoblastic disease. The binding of hCG to LHCGR is essential for corpus luteum maintenance. Structural features of mammalian gonadotropins, including hCG, have been reviewed in the context of their biological functions. Thus, studying choriogonadotropin hormone binding can inform the pathophysiology of pregnancy-related disorders.
From choriogonadotropin hormone binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LHCGR mediate high-affinity hCG binding? | LHCGR knockout cell line (e.g., HEK293) with radioligand binding assay |
| Which residues dictate hCG versus LH binding specificity? | Point mutations in LHCGR extracellular domain |
| Is Asp397 required for receptor activation but not binding? | Point mutation (Asp397Ala) knock-in in LHCGR |
| Can small molecules selectively modulate LHCGR? | Overexpression of LHCGR in reporter cell lines for high-throughput screening |
| How do extracellular loop deletions affect binding? | Deletion mutants of LHCGR expressed in cell lines |
| What is the role of exoloop 2 in high-affinity binding? | Chimeric or point-mutated receptors in binding assays |
How to Study the choriogonadotropin hormone binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity (Kd) and receptor density (Bmax) | Characterizing wild-type and mutant LHCGR |
| Cryo-EM | 3D structure of hormone-receptor complex | Visualizing binding interface and activation |
| Site-directed mutagenesis | Effect of specific residues on binding/activation | Mapping functional epitopes |
| Deletion mutagenesis | Role of extracellular loops in binding | Ligand-specific requirements |
| cAMP accumulation assay | Downstream signaling after binding | Distinguishing binding from activation |
| Surface plasmon resonance | Real-time binding kinetics | Measuring affinity and kinetics |
| Small-molecule screening | Identification of modulators | Drug discovery for LHCGR/TSHR |
| Immunoassays | Hormone levels in samples | Diagnosis of pregnancy and tumors |
Radioligand binding assays
Radioligand binding assays using iodinated hCG are a classic method to measure affinity and specificity of choriogonadotropin hormone binding. These assays can be performed on intact cells or membrane preparations expressing wild-type or mutant receptors. They allow determination of dissociation constants and competition with unlabeled ligands.
Structural biology (cryo-EM and crystallography)
Cryo-electron microscopy has been used to solve structures of full-length glycoprotein hormone receptor signalling complexes, revealing the binding interface between hCG and LHCGR. These structures provide atomic-level details of the hormone-receptor interaction and conformational changes upon activation. Such information is invaluable for rational drug design.
Mutagenesis and functional assays
Site-directed mutagenesis of the receptor extracellular domain, followed by binding and signaling assays, has identified residues critical for hormone binding and activation. Deletion analysis of extracellular loops has shown their differential roles in binding LH versus hCG. Exoloop 2 has been implicated in modulating high-affinity binding.
Small-molecule screening and pharmacology
High-throughput screening of small-molecule libraries against LHCGR and TSHR has identified modulators with selective binding patterns. These compounds can be used to probe the binding mechanism and as starting points for drug development. Structure-activity relationship studies help optimize potency and selectivity.
How CRISPR Can Be Used to Study GO:0038106 choriogonadotropin hormone binding
Knockout
CRISPR knockout of LHCGR or the hCG subunit genes (CGA, CGB) can abolish choriogonadotropin hormone binding in cell models, providing a clean background to study binding specificity. Knockout of LHCGR in HEK293 or Leydig cell lines followed by radioligand binding assays can confirm the receptor's role. Such models are essential for validating drug targets and understanding loss-of-function phenotypes.
Point Mutation
Point mutations can be introduced into LHCGR to dissect the binding interface, for example substituting Asp397 to test its role in activation versus binding. Mutations in extracellular domain residues can alter affinity for hCG versus LH, as shown by previous mutagenesis studies. CRISPR-based point mutation allows precise modeling of naturally occurring variants associated with reproductive disorders.
Knock-in
Knock-in of tagged or reporter versions of LHCGR or hCG subunits enables real-time tracking of binding and trafficking. For example, a fluorescent tag can be inserted into the receptor to monitor cell surface expression and ligand-induced internalization. Knock-in of disease-associated mutations can create isogenic models for drug testing.
Overexpression
Overexpression of LHCGR in heterologous cells is widely used to study hormone binding and signaling, as it provides a high signal-to-noise ratio for binding assays. Overexpression of hCG subunits can produce bioactive hormone for binding studies. This approach is also useful for high-throughput screening of small-molecule modulators.
How EDITGENE Supports choriogonadotropin hormone binding Research
Researchers studying choriogonadotropin hormone binding-related genes often need to determine whether a candidate gene is causally involved in hormone recognition, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models that enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for choriogonadotropin hormone binding research.
Frequently Asked Questions About choriogonadotropin hormone binding
What is choriogonadotropin hormone binding?
Choriogonadotropin hormone binding (GO:0038106) is the molecular function of binding to choriogonadotropin (hCG), a heterodimeric hormone with a shared alpha subunit and a unique beta subunit.
What genes are involved in choriogonadotropin hormone binding?
Key genes include LHCGR (the receptor), CGA (alpha subunit), and CGB (beta subunit of hCG), as well as related glycoprotein hormone genes.
Which receptor binds choriogonadotropin?
The luteinizing hormone/choriogonadotropin receptor (LHCGR) is the primary receptor that binds hCG with high affinity.
How does hCG binding differ from LH binding?
Different extracellular domain residues of LHCGR dictate binding affinities for LH versus hCG, allowing discrimination between the two hormones.
What is the role of Asp397 in the LHCGR receptor?
Asp397 is important for receptor activation but not for hormone binding, indicating that binding and activation are separable steps.
Can small molecules modulate choriogonadotropin hormone binding?
Yes, small-molecule modulators of LHCGR and TSHR have been identified, with selective binding patterns and structure-activity relationships.
What diseases are associated with abnormal choriogonadotropin hormone binding?
Mutations in LHCGR can cause reproductive disorders, and hCG/LHCGR signaling is implicated in some cancers and gestational diseases.
How can CRISPR be used to study choriogonadotropin hormone binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of receptor and ligand genes in cell lines.
What methods measure choriogonadotropin hormone binding?
Radioligand binding assays, surface plasmon resonance, and structural biology (cryo-EM) are commonly used to measure and visualize binding.
Why is choriogonadotropin hormone binding important for pregnancy?
hCG binding to LHCGR maintains the corpus luteum and supports progesterone production, which is essential for early pregnancy.
Conclusion
Choriogonadotropin hormone binding (GO:0038106) is a fundamental molecular function that governs the specific recognition of human chorionic gonadotropin by its receptor LHCGR. Through a combination of structural biology, mutagenesis, and pharmacological studies, researchers have mapped the key determinants of binding affinity and distinguished binding from receptor activation. This knowledge has direct implications for reproductive medicine, cancer biology, and drug discovery. CRISPR-based cell models offer powerful tools to further dissect the genetic and molecular basis of this interaction, and EDITGENE provides end-to-end services to support such research.
References
- 1. Duan J et al.. 2021. Structures of full-length glycoprotein hormone receptor signalling complexes.. Nature 598(7882):688-692 PMID: 34552239
- 2. Galet C et al.. 2005. The differential binding affinities of the luteinizing hormone (LH)/choriogonadotropin receptor for LH and choriogonadotropin are dictated by different extracellular domain residues.. Mol Endocrinol 19(5):1263-76 PMID: 15677709
- 3. Ji I et al.. 1993. Receptor activation is distinct from hormone binding in intact lutropin-choriogonadotropin receptors and Asp397 is important for receptor activation.. J Biol Chem 268(28):20851-4 PMID: 8407915
- 4. Moore S et al.. 2006. Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns.. J Med Chem 49(13):3888-96 PMID: 16789744
- 5. Abell A et al.. 1996. Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor.. J Biol Chem 271(8):4518-27 PMID: 8626807
- 6. Ryu K et al.. 1998. Modulation of high affinity hormone binding. Human choriogonadotropin binding to the exodomain of the receptor is influenced by exoloop 2 of the receptor.. J Biol Chem 273(11):6285-91 PMID: 9497355
- 7. Thomas D et al.. 1996. Mutational analyses of the extracellular domain of the full-length lutropin/choriogonadotropin receptor suggest leucine-rich repeats 1-6 are involved in hormone binding.. Mol Endocrinol 10(6):760-8 PMID: 8776736
- 8. Bousfield GR et al.. 1996. Structural features of mammalian gonadotropins.. Mol Cell Endocrinol 125(1-2):3-19 PMID: 9027339
